Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 3/20 | 0.68 |
| ▸ | PLCG1 | P19174 | 4/20 | 0.56 |
| ▸ | PLCB3 | Q01970 | 4/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 7/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17860519 | 0.92 | PAX8 (0.60) | PAX8PLCG1PLCB3CASP6ACKR3 | |
| SCHEMBL17860409 | 0.91 | PAX8 (0.75) | PAX8PLCG1PLCB3CASP6ACKR3 | |
| SCHEMBL17860520 | 0.88 | PLCG1 (0.55) | PAX8PLCG1PLCB3CASP6BACE1 | |
| SCHEMBL17860435 | 0.85 | PAX8 (0.67) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL17860468 | 0.83 | PAX8 (0.65) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL16984262 | 0.83 | PAX8 (0.65) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL16980367 | 0.83 | PAX8 (0.65) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL17860436 | 0.81 | PLCG1 (0.66) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL17860300 | 0.81 | PAX8 (0.60) | PAX8PLCG1PLCB3CASP6 | |
| SCHEMBL17860327 | 0.80 | CASP6 (0.73) | PAX8PLCG1PLCB3CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016100711-A1 | MODULATORS OF HEPATIC LIPOPROTEIN METABOLISM | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20150166601-A1 | DEUTERATED CARFILZOMIB | CONCERT PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166601-A1 | DEUTERATED CARFILZOMIB | BCL9, DOT1L, U2AF1 | PAX8 1090/4885PLCG1 3826/4885PLCB3 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.